- White light cystoscopy (“WLC”) is the most commonly used procedure to detect non-muscle invasive bladder cancer (“NMIBC”)
- Despite its prevalence, WLC is not the most effective method and contributes to a high bladder cancer recurrence rate
- Blue light cystoscopy (“BLC”) is a more recent and highly effective method, but the high cost of equipment and skill level has impeded its uptake among hospitals
- Imagin Medical believes the i/Blue(TM) Imaging System , which displays white and blue light images side by side, will address these issues
- It eliminates the need to purchase new cystoscopes. The i/Blue System’s dual-view camera head can attach to almost any cystoscope, lowering the cost of entry
- i/Blue Imaging System is a cost saver for hospitals and patients
The benefits of blue light cystoscopy (“BLC”) have been documented since 2010, when the FDA first approved the use of hexaminolevulinate HCL (“HAL”), an imaging agent that, when absorbed by cancerous cells, distinguishes them from healthy cells when exposed to blue light. However, despite this knowledge being in the public domain and the American Urology Association recommending the use of blue light, its uptake in the visualization, location, and subsequent resection of tumors in the bladder has been slow.
According to Imagin Medical (CSE: IME) (OTCQB: IMEXF), a company focusing on establishing a new standard of care in visualizing cancer…
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.